Touchstone International Medical Science Co., Ltd. (688013.SS)
CNY 19.03
(-0.73%)
CNY 19.03
(-0.73%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 57.97 Million CNY | 2.09% |
| 2022 | 54.79 Million CNY | 48.89% |
| 2021 | 35.63 Million CNY | -22.94% |
| 2020 | 46.88 Million CNY | -15.19% |
| 2019 | 54.65 Million CNY | 74.14% |
| 2018 | 31.53 Million CNY | 126.93% |
| 2017 | 18.24 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 17.27 Million CNY | 15.7% |
| 2024 Q3 | 16.36 Million CNY | -5.14% |
| 2024 Q1 | 13.03 Million CNY | 4.7% |
| 2023 Q3 | 5.82 Million CNY | -63.72% |
| 2023 FY | - CNY | 2.09% |
| 2023 Q4 | 11.01 Million CNY | 89.1% |
| 2023 Q2 | 16.05 Million CNY | 38.76% |
| 2023 Q1 | 11.56 Million CNY | 42.21% |
| 2022 Q3 | 15.36 Million CNY | 45.55% |
| 2022 Q2 | 10.55 Million CNY | -1.01% |
| 2022 Q1 | 10.66 Million CNY | 270.57% |
| 2022 FY | - CNY | 48.89% |
| 2022 Q4 | 8.13 Million CNY | -47.07% |
| 2021 Q1 | 10.05 Million CNY | -31.86% |
| 2021 Q4 | 2.87 Million CNY | -59.46% |
| 2021 FY | - CNY | -22.94% |
| 2021 Q3 | 7.1 Million CNY | -15.36% |
| 2021 Q2 | 8.38 Million CNY | -16.58% |
| 2020 Q3 | 10.83 Million CNY | 367.85% |
| 2020 Q1 | 18.07 Million CNY | 122.4% |
| 2020 Q2 | -4.04 Million CNY | -122.38% |
| 2020 FY | - CNY | -15.19% |
| 2020 Q4 | 14.75 Million CNY | 36.23% |
| 2019 FY | - CNY | 74.14% |
| 2019 Q3 | 15.42 Million CNY | 203.69% |
| 2019 Q2 | 5.07 Million CNY | -74.45% |
| 2019 Q1 | 19.87 Million CNY | 0.0% |
| 2019 Q4 | 8.12 Million CNY | -47.31% |
| 2018 FY | - CNY | 126.93% |
| 2017 FY | - CNY | 0.0% |